Spensus Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Spensus Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gr…

2018-02-24 Kadi, Gujarat Active Unlisted
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Spensus Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
72/100
Trust Score
Moderate

Spensus Pharmaceuticals Private Limited is assessed as Moderate with a Trust Score of 72/100. Spensus Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2018, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 28 Oct 2026 from the latest processed filings. Spensus Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
25/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 25/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.

Charges position: 4 open (17.98 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Sidbi4 48.0 cr
Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2024 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
NILESHKUMAR HARIBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
TANMAY NATVARBHAI PATEL 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
EPFO headcount growing - hiring signal.
Operating for 8 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Statutory filings appear overdue.
4 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment45/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 17.98 cr already registered.
  • Compliance record supports lending.
Investor view70/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
27 Aug 2024
Charge created
Sidbi - 3.48 cr
31 Mar 2024
Latest balance sheet
Filed with ROC
31 Mar 2022
Securities allotted
3990000 Equity Shares - 3.99 cr raised
13 Jan 2022
Charge created
Sidbi - 9.00 cr
Charge created
Sidbi - 5.00 cr
Charge created
Sidbi - 50.00 Lakh
31 Mar 2021
Share transfer (FY 2021)
500.00000000 shares to TANMAY NATVARBHAI PATEL
Share transfer (FY 2021)
3500.00000000 shares to NILESHKUMAR HARILAL PATEL
Share transfer (FY 2021)
500.00000000 shares to NILESHKUMAR HARILAL PATEL
07 Sep 2020
Director ceased
HARILAL BHAGVANDAS PATEL
Director ceased
KINJALBEN NILESHKUMAR PATEL
Director ceased
NATVARLAL VITTHALBHAI PATEL
24 Feb 2018
Incorporated
Registered with Roc Ahmedabad
Director appointed
NILESHKUMAR HARIBHAI PATEL (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Bracing Pharmaceutical Private Limited U74999GJ2017PTC096872 Mehsana, Gujarat, India
Avizen Biopharma Private Limited U24304AS2016PTC017532 Guwahati, Assam, India
Pramukh Swami Pharma Limited U24231GJ1997PLC032344 Gandhinagar, Gujarat, India
Gliesse Pharmaceuticals Private Limited U24110GJ2020PTC115404 Ahmedabad, Gujarat, India
Whiz Laboratories India U51397PB2000PTC023326 Ludhiana, Punjab, India
Sun Adhesives & Chemicals Private Limited U24233MH2013PTC244576 Mumbai, Maharashtra, India
Rahul Orthotics Instruments Private Limited U74120UP2011PTC046320 Aligarh, Uttar Pradesh, India
Panexcell Clinical U24239MH2006PTC164765 Navi Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Spensus Pharmaceuticals Private Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Spensus Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 25/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Spensus Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Spensus Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Spensus Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Spensus Pharmaceuticals Private Limited an active company?

Spensus Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Spensus Pharmaceuticals Private Limited financially healthy?

Spensus Pharmaceuticals Private Limited has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.

Should I do business with Spensus Pharmaceuticals Private Limited?

Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Spensus Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Spensus Pharmaceuticals Private Limited have loans or charges against its assets?

4 open charge(s) are registered against its assets.

Is Spensus Pharmaceuticals Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2024 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Spensus Pharmaceuticals Private Limited?

Its Credit Risk Score is 25/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.